The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. - Wikidata - awgldk - TriplyDB

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

http://www.wikidata.org/entity/Q34540035

about

New and emerging disease modifying therapies for multiple sclerosis Ofatumumab for rheumatoid arthritis Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia Ofatumumab: a novel monoclonal anti-CD20 antibody The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia Ofatumumab An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)New developments in the management of chronic lymphocytic leukemia: role of ofatumumab Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics New antibody approaches to lymphoma therapy Monoclonal antibodies for the treatment of cancer Structural basis for recognition of CD20 by therapeutic antibody Rituximab Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment Statins impair antitumor effects of rituximab by inducing conformational changes of CD20 Affinity is an important determinant of the anti-trypanosome activity of nanobodies Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.In silico designing, cloning, and heterologous expression of novel chimeric human B lymphocyte CD20 extra loop.Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.Complement is activated by IgG hexamers assembled at the cell surface.Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Synthetic antibodies as therapeutics.Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.The clinical development of obinutuzumab for the treatment of follicular lymphoma.A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy Management of chronic lymphocytic leukemia.Prevention trumps treatment of antibody-mediated transplant rejection Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4

P2860

Q22242305-CD4DDA8C-2500-45AF-8CF9-4CA2CCACAC04 Q24202719-708313AC-A5D3-4071-9AA0-E2CE536102BE Q24203027-D167D223-DC92-4756-8C91-1E8AA18726DB Q24604065-82113206-99ED-491D-A099-61B4504DEF6F Q24605471-EDC952FE-EEB9-423B-9758-18765477F183 Q24617708-95C66391-5578-4EDC-819E-A7F633890F87 Q24651912-2D615461-1187-4C70-90B3-A933184F65B5 Q26748601-0467FCAD-F868-4C33-A882-7CB49518A68D Q26768154-CF4EEE7A-601C-49BE-83E5-7ADD793599C8 Q26768396-18487725-1ED9-48C3-871D-4ECD8035F8F0 Q26849243-D4C100D4-0480-4DD1-B6C0-AB59F7FA9530 Q27022373-C5FC062A-18C4-4C4A-892F-02513CBCB54E Q27025966-C0BCD45A-9EDA-4371-B633-D2929B3057DC Q27644280-68D4CE48-302C-4151-82E3-02B039B02EA2 Q28082086-A3A34B5E-FDB5-4F26-8DF4-80FCBE7DB9F3 Q28472420-612700E5-147C-4F72-A3B0-C892275E129D Q28485195-2B0233CF-096C-4A51-B5DF-89DDF0C3F49E Q30303054-9C1B1252-128E-4AED-BD00-6FF55052268E Q30356145-6F00584F-4FD5-424E-91E5-8390E643D207 Q30389864-52A9E0B3-C4CE-499F-8EDC-D05B88D2590D Q30405847-27CEA307-3D6C-4C53-BF5F-5BEC3388CB63 Q30409381-C8CACE6A-3B04-4135-9F6C-262771F831D4 Q30421637-8AD1DB64-D85C-4E45-8451-E8AF821B9F91 Q30439017-4DEE5F76-760D-4737-98FC-19889A9B8021 Q30440293-21CBC380-1BC4-4208-B6E0-53E5E88A7286 Q30453680-0829027D-78F4-45BD-9F5E-C77C970AAA4C Q30500362-C3525336-BFA7-4890-8719-9D20AC874069 Q30764873-342D4B27-D085-4623-83B4-0A2C4C7DD66A Q33265617-E1D7E670-4764-46E4-B3D3-8936DED6F347 Q33394947-7E7BDC39-285B-474D-AC36-08CA0F920A31 Q33407700-FF98E85D-E8D9-43F4-8F4C-92ACD7AB4109 Q33410306-3759C33B-A388-4247-BA76-40F0D9A0C5CE Q33419843-2E13EB0E-474B-4BA9-8D4A-EF1A4865BD54 Q33565265-FDA531B4-BB9F-4370-B702-F2161D6FE73F Q33573612-9DACFA14-826A-48ED-A365-2968BD987BCC Q33695912-148D037E-1226-445E-A8BE-C246CE54EADD Q33755462-2A4DF0BC-1512-4B7F-95C6-8F14B890CD9D Q33798060-F3C391DB-FD35-4C4E-BF00-060356262809 Q33896738-B95BD495-9D56-4EA1-A8CA-4A0C1E3938F2 Q34055092-F67D6B5A-BF1B-4C99-8103-79EE428A3B0C

P2860

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

http://www.wikidata.org/entity/Q34540035

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

The biological activity of hum ...... ed to unique epitopes on CD20.

@ast

The biological activity of hum ...... ed to unique epitopes on CD20.

@en

The biological activity of hum ...... ed to unique epitopes on CD20.

@nl

type

label

The biological activity of hum ...... ed to unique epitopes on CD20.

@ast

The biological activity of hum ...... ed to unique epitopes on CD20.

@en

The biological activity of hum ...... ed to unique epitopes on CD20.

@nl

prefLabel

The biological activity of hum ...... ed to unique epitopes on CD20.

@ast

The biological activity of hum ...... ed to unique epitopes on CD20.

@en

The biological activity of hum ...... ed to unique epitopes on CD20.

@nl

P1433

Q34540035-71D788D9-029B-4B5F-B2A2-F4F1E67DC2F0

P1476

Q34540035-E3CE43F2-E98A-4F9C-A1FF-EF585E720B88

P2093

Q34540035-00087F97-61F0-431D-8432-8282195B6B4D

Q34540035-0FF1C7E3-9512-485D-8D61-17FB888BB27E

Q34540035-18802588-CC58-4934-B68F-D852A02505AE

Q34540035-39C8108F-8586-4782-BB20-74649B5A7D8B

Q34540035-47145B7F-751E-46DC-8D9D-0D618D3F90D1

Q34540035-51E83C65-BFD2-466D-9252-F5536526D5C9

Q34540035-56D62DA3-46C0-490E-8619-8611ED4DD89C

Q34540035-8448C3FC-DE9B-4F03-BE71-918D2D2299A6

Q34540035-AC9FBCDB-378C-4847-AD21-6F934D0EA4C0

Q34540035-BE7BC072-B12E-42B7-9C04-1FBA2C99A6FC

P304

Q34540035-D7251CE3-07C2-4C98-8EFC-4AEB6C09064B

P31

Q34540035-7E285721-C1E0-4EA9-8F95-7A18D576C809

P356

Q34540035-E7C01F8D-9DA8-4E64-875B-E8E8C4523EB2

P407

Q34540035-902E9057-00D2-48F0-BE92-D7CC4DCB21F8

P433

Q34540035-9074656A-DDEC-42AB-B784-64C1047E0D58

P478

Q34540035-554D2DD2-C5B3-41EE-8252-B784923C06F4

P577

Q34540035-A8F9F1BA-B009-4009-ADA1-149EF130BA64

P5875

Q34540035-408BCD13-78BB-4F5E-BC30-EC2F7A3C5CF3

P698

Q34540035-7AA20627-2179-4010-A1C8-95977A35568D

P921

Q34540035-9BEEC156-BD20-485A-BA55-B1A7071617B0

P356

JIMMUNOL.177.1.362

P1433

Journal of Immunology

P1476

The biological activity of hum ...... ed to unique epitopes on CD20.

@en

P2093

Jan G J van de Winkel

http://www.w3.org/2001/XMLSchema#string

Jeroen H N van den Brakel

http://www.w3.org/2001/XMLSchema#string

Jerry W Slootstra

http://www.w3.org/2001/XMLSchema#string

Jessica L Teeling

http://www.w3.org/2001/XMLSchema#string

Luus J J M Wiegman

http://www.w3.org/2001/XMLSchema#string

Martin J Glennie

http://www.w3.org/2001/XMLSchema#string

Paul W H I Parren

http://www.w3.org/2001/XMLSchema#string

Ruth R French

http://www.w3.org/2001/XMLSchema#string

Saskia Ebeling

http://www.w3.org/2001/XMLSchema#string

Stephen A Beers

http://www.w3.org/2001/XMLSchema#string

P304

362-371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.177.1.362

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6997700

http://www.w3.org/2001/XMLSchema#string

P698

16785532

http://www.w3.org/2001/XMLSchema#string

P921